Actavis' (ACT) Move to Acquire Durata (DRTX) is Strategically Sound; Signals Appetite for More M&A - Moody's
Get Alerts ACT Hot Sheet
Join SI Premium – FREE
Moody's Investors Service commented that Actavis plc's (NYSE: ACT) acquisition of Durata Therapeutics Inc. (Nasdaq: DRTX) is strategically sound, but signals continued appetite for acquisitions at a a time when the company is still integrating its $28 billion acquisition of Forest Laboratories. There is no change to Actavis' Baa3 senior unsecured rating or the stable outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Home Depot's deal 'likely a positive for BECN" - Stifel Reiterates Beacon (BECN) at Buy
- Highest Performances Holdings (HPH) Acquires 78% Stake in Singapore White Lingjun
- Tricon Residential (TCN) Shareholders Approve Proposed Take Private by Blackstone Real Estate
Create E-mail Alert Related Categories
Credit RatingsRelated Entities
Moody's Investors Service, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!